1 results match your criteria: "Hospital Affiliated Academy of Military Medical Sciences[Affiliation]"
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Zhonghua Zhong Liu Za Zhi
June 2004
Department of Breast Cancer, Hospital Affiliated Academy of Military Medical Sciences, Beijing 100039, China.
Objective: To evaluate the efficacy and adverse reactions of Xeloda in the treatment of recurrent and metastatic breast cancer.
Methods: This clinical study was designed to treat 69 patients with recurrent and metastatic breast cancer with Xeloda, 2500 mg/m(2)/d, twice daily for 2 weeks followed by a 1-week rest period, repeated every 3 weeks.
Results: Sixty-nine patients received Xeloda for more than 1 cycle.